Fuzapladib (sodium)

Fuzapladib (IS-741) sodium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib sodium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib sodium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site[1][2].

Product Specifications

CAS Number

[141284-73-3]

Product Name Alternative

IS-741 (sodium)

UNSPSC

12352005

Target

Integrin; Phospholipase

Type

Reference compound

Related Pathways

Cytoskeleton; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/fuzapladib-sodium.html

Purity

99.61

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1CCCCC1)NC2=CC(C(F)(F)F)=CN=C2NS(=O)(CC)=O.[Na]

Molecular Formula

C15H20F3N3NaO3S

Molecular Weight

402.39

References & Citations

[1]Shikama H, et al. Effect of IS-741 on cell adhesion between human umbilical vein endothelial cells and HL-60 cells. Biol Pharm Bull. 1999 Feb;22 (2) :127-31.|[2]Tetsuya Fukunaga, et al. A novel diamino-pyridine derivative (IS-741) attenuates rat ileitis induced by trinitrobenzene sulfonic acid. J Gastroenterol. 2003;38 (5) :451-9.|[3]Noriyuki Kaji, et al. Fuzapladib reduces postsurgical inflammation in the intestinal muscularis externa. J Vet Med Sci. 2023 Sep 21.|[4]C Bassi. IS-741 (Ishihara Sangyo) . Curr Opin Investig Drugs. 2001 Apr;2 (4) :510-2.